Anti–Tumor Necrosis Factor-α Antibody Limits Heart Failure in a Transgenic Model
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background — Tumor necrosis factor (TNF)-α has been implicated in the pathophysiology of congestive heart failure. A strain of transgenic mice (TNF1.6) with cardiac-specific overexpression of TNF-α develop congestive heart failure. Methods and Results — To determine the effect of anti-TNF-α therapy in this model, we studied 3 groups: TNF1.6 mice treated with saline, wild-type mice treated with saline, and TNF1.6 mice treated with TNF-α neutralizing antibody (cV1q) from 6 to 12 weeks of age. We used echocardiography to compare cardiac hypertrophy, function, and catecholamine response at 12 weeks of age versus baseline (6 weeks). cV1q treatment did not limit cardiac hypertrophy, but it significantly improved basal fractional shortening and responsiveness to β-adrenergic stimulation, and it limited development of cardiac dilation. Conclusions — Blockade of TNF-α bioactivity by antibody therapy may both preserve cardiac function and partially reverse pathological changes in congestive heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Bozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., Seta, Y., Oral, H., Spinale, F. G., & Mann, D. L. (1998) · Circulation · doi:10.1161/01.cir.97.14.1382 · Cited by 821
Cited by
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907
Cardiomyocyte death: mechanisms and translational implications
Chiong, M., Wang, Z. V., Pedrozo, Z., Cao, D. J., Troncoso, R., Ibacache, M., Criollo, A., Nemchenko, A., Hill, J. A., & Lavandero, S. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.130 · Cited by 491
Wolfe, F., & Michaud, K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.039 · Cited by 372
Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., & Rosenblum, K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00480 · Cited by 254
Yang, Z.-S., Lin, N.-N., Li, L., & Li, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8560-9 · Cited by 123
Short- and long-term effects of IL-1 and TNF antagonists on periodontal wound healing
Zhang, X., Kohli, M., Zhou, Q., Graves, D. T., & Amar, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3514 · Cited by 71
“Neutralizing Abs to IL-1/TNF were found to be beneficial in diseases associated with excessive IL-1/TNF production (51, 52).”
Background
Metadata
- Authors
- Kadokami, T., Frye, C., Lemster, B., Wagner, C. L., Feldman, A. M., & McTiernan, C. F.
- Venue
- Circulation
- Published
- 2001-09-04
- Volume
- 104
- Issue
- 10
- Pages
- 1094-1097
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2143514809
- Cited by
- 97
- References
- 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.